Publications by authors named "Paul Passier"

Claim this Profile
H
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example.
Claudia Meyer, Ines Dierick, Glenn Gauderat, Jurgen Langenhorst, Céline Sarr, Paul Passier

Clin Pharmacol Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate-Severe Atopic Dermatitis.
Diamant Thaçi, Dave Singh, Mark Lee, Helen Timmis, Dominique Jacobs, Paul Passier

J Clin Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip.
Ellen van der Aar, Henri Deckx, Sonia Dupont, Ann Fieuw, Stephane Delage, Paul Passier

Clin Pharmacol Drug Dev· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
Søren Rittig, Małgorzata Baka-Ostrowska, Camilla Tøndel, Johan Vande Walle, Birgitta Kjaeer, Paul Passier

J Pediatr Urol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
Nicoline Treijtel, Christiane Collins, Michel van Bruijnsvoort, Rainard Fuhr, Etienne Ernault, Paul Passier

Clin Pharmacol Drug Dev· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Randomized, Double-Blind, Laser-Evoked Potential Study to Evaluate the Analgesic/Antihyperalgesic Effect of ASP9226, a State-Dependent N-Type Voltage-Gated Calcium Channel Inhibitor, in Healthy Male Subjects.
Klaus Schaffler, Weizhong He, Paul Passier, Katherine Tracy, Allam Fakhoury

Pain Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale.
Peter L Bonate, Tianli Wang, Paul Passier, Wilhelmina Bagchus, Howard Burt

J Pharmacokinet Pharmacodyn· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects.
Klaus Schaffler, Ashraf Yassen, Peter Reeh, Paul Passier

Pain Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational PK-PD modeling in pain.
Ashraf Yassen, Paul Passier, Yasuhisa Furuichi, Albert Dahan

J Pharmacokinet Pharmacodyn· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups.
Christian Martini, Ashraf Yassen, Erik Olofsen, Paul Passier, Malcom Stoker

J Pain Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sugammadex is cleared rapidly and primarily unchanged via renal excretion.
Pierre Peeters, Paul Passier, Jean Smeets, Alex Zwiers, Marcel de Zwart

Biopharm Drug Dispos· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.
Paul Ratcliffe, Julia M Adam, James Baker, Roberta Bursi, Robert Campbell, Paul Passier

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study.
Pierre A M Peeters, Michiel W van den Heuvel, Emiel van Heumen, Paul C C M Passier, Jean M W Smeets

Clin Drug Investig· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers.
Lineke Zuurman, Paul C C M Passier, Marieke L de Kam, Huub J Kleijn, Adam F Cohen

J Psychopharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis